Business · 09/01/2024
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Thermally Responsive T Cell Therapies for the Treatment of HPV-Positive Cancer(s)
The National Cancer Institute is considering granting an Exclusive Patent License to Port Therapeutics, Inc. for the development and commercialization of thermally responsive T cell therapies for HPV-positive cancer treatment.